Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Size, Share, Trends and Forecast 2022-2030

Description

Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of many cancer treatments. Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families. In 1983, Coates et al. found that patients receiving chemotherapy ranked nausea and vomiting as the first and second most severe side effects, respectively. Up to 20% of patients receiving highly emetogenic agents in this era postponed, or even refused, potentially curative treatments. Since the 1990s, several novel classes of antiemetics have been developed and commercialized, becoming a nearly universal standard in chemotherapy regimens, and helping to better manage these symptoms in a large portion of patients. Efficient mediation of these unpleasant and sometimes crippling symptoms results in increased quality of life for the patient, and better overall health of the patient, and, due to better patient tolerance, more effective treatment cycles.
Affecting 70-80% of patients undergoing chemotherapy, chemotherapy-induced nausea and vomiting (CINV) is one of chemotherapy's most debilitating side effects, often attributed as a leading cause of premature discontinuation of cancer treatment.

Industry Insights

Due to the COVID-19 pandemic, the global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs market size is estimated to be worth US$ 2363 million in 2021 and is forecast to a readjusted size of US$ 2107.8 million by 2028 with a CAGR of -1.6% during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.

Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs key players include Haisco, Merck, Mundipharma, Qilu Pharma, Heron Therapeutics, Teva, etc. Global top six manufacturers hold a share about 30%.

North America is the largest market, with a share about 35%, followed by Europe and Asia-Pacific, both have a share about 60 percent.

In terms of product, 5-HT3 Inhibitors is the largest segment, with a share over 70%. And in terms of application, the largest application is Acute CINV, followed by Delayed CINV and Breakthrough CINV.

This report focuses on Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China, Japan and India, etc.

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Post-covid-19 Outlook

The readers in the section will understand how the Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs market scenario changed across the globe during the pandemic and post-pandemic. The study is done keeping in view the changes in aspects such as sales, demand and supply chain. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Segmental Outlook

Key segments including type and application have been elaborated in this report. The consultants at QY Research have studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and application during the historical period (2017-2022) and forecast period (2023-2028).

Segment by Type

5-HT3 Inhibitors

NK1 Inhibitors

Others

Segment by Application

Acute CINV

Delayed CINV

Breakthrough CINV

Others

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028. This information derived through comprehensive research will help the reader to get familiar with the potential value of the investment in a particular region.

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Indonesia

Thailand

Malaysia

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Competitive Scenario

In this section, the readers will gain an understanding of the key players competing. The experts at QY Research have studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

Heron Therapeutics

Merck

Eisai

Mundipharma

Qilu Pharma

Teva

Novartis

Roche

Mylan

Baxter

GSK

Helsinn

Southwest Pharma

Haisco

Sun Pharma

TABLE OF CONTENT

1 Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Overview
1.1 Product Overview and Scope of Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs

1.2 Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Segment by Type

1.2.1 Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Sales Growth Rate Comparison by Type (2022-2028)

1.2.2 5-HT3 Inhibitors

1.2.3 NK1 Inhibitors

1.2.4 Others

1.3 Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Segment by Application

1.3.1 Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Sales Comparison by Application: (2022-2028)

1.3.2 Acute CINV

1.3.3 Delayed CINV

1.3.4 Breakthrough CINV

1.3.5 Others

1.4 Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Size Estimates and Forecasts

1.4.1 Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Revenue 2017-2028

1.4.2 Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Sales 2017-2028

1.4.3 Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Size by Region: 2017 Versus 2021 Versus 2028

2 Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Competition by Manufacturers

2.1 Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Sales Market Share by Manufacturers (2017-2022)

2.2 Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Revenue Market Share by Manufacturers (2017-2022)

2.3 Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Average Price by Manufacturers (2017-2022)

2.4 Manufacturers Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Manufacturing Sites, Area Served, Product Type

2.5 Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Competitive Situation and Trends

2.5.1 Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Concentration Rate

2.5.2 The Global Top 5 and Top 10 Largest Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Players Market Share by Revenue

2.5.3 Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Retrospective Market Scenario by Region

3.1 Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Retrospective Market Scenario in Sales by Region: 2017-2022

3.2 Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Retrospective Market Scenario in Revenue by Region: 2017-2022

3.3 North America Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Facts & Figures by Country

3.3.1 North America Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Sales by Country

3.3.2 North America Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Revenue by Country

3.3.3 United States

3.3.4 Canada

3.4 Europe Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Facts & Figures by Country

3.4.1 Europe Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Sales by Country

3.4.2 Europe Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Revenue by Country

3.4.3 Germany

3.4.4 France

3.4.5 U.K.

3.4.6 Italy

3.4.7 Russia

3.5 Asia Pacific Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Facts & Figures by Region

3.5.1 Asia Pacific Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Sales by Region

3.5.2 Asia Pacific Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Revenue by Region

3.5.3 China

3.5.4 Japan

3.5.5 South Korea

3.5.6 India

3.5.7 Australia

3.5.8 China Taiwan

3.5.9 Indonesia

3.5.10 Thailand

3.5.11 Malaysia

3.6 Latin America Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Facts & Figures by Country

3.6.1 Latin America Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Sales by Country

3.6.2 Latin America Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Revenue by Country

3.6.3 Mexico

3.6.4 Brazil

3.6.5 Argentina

3.7 Middle East and Africa Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Facts & Figures by Country

3.7.1 Middle East and Africa Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Sales by Country

3.7.2 Middle East and Africa Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Revenue by Country

3.7.3 Turkey

3.7.4 Saudi Arabia

3.7.5 UAE

4 Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Historic Market Analysis by Type

4.1 Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Sales Market Share by Type (2017-2022)

4.2 Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Revenue Market Share by Type (2017-2022)

4.3 Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Price by Type (2017-2022)

5 Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Historic Market Analysis by Application

5.1 Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Sales Market Share by Application (2017-2022)

5.2 Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Revenue Market Share by Application (2017-2022)

5.3 Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Price by Application (2017-2022)

6 Key Companies Profiled

6.1 Heron Therapeutics

6.1.1 Heron Therapeutics Corporation Information

6.1.2 Heron Therapeutics Description and Business Overview

6.1.3 Heron Therapeutics Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Sales, Revenue and Gross Margin (2017-2022)

6.1.4 Heron Therapeutics Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Portfolio

6.1.5 Heron Therapeutics Recent Developments/Updates

6.2 Merck

6.2.1 Merck Corporation Information

6.2.2 Merck Description and Business Overview

6.2.3 Merck Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Sales, Revenue and Gross Margin (2017-2022)

6.2.4 Merck Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Portfolio

6.2.5 Merck Recent Developments/Updates

6.3 Eisai

6.3.1 Eisai Corporation Information

6.3.2 Eisai Description and Business Overview

6.3.3 Eisai Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Sales, Revenue and Gross Margin (2017-2022)

6.3.4 Eisai Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Portfolio

6.3.5 Eisai Recent Developments/Updates

6.4 Mundipharma

6.4.1 Mundipharma Corporation Information

6.4.2 Mundipharma Description and Business Overview

6.4.3 Mundipharma Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Sales, Revenue and Gross Margin (2017-2022)

6.4.4 Mundipharma Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Portfolio

6.4.5 Mundipharma Recent Developments/Updates

6.5 Qilu Pharma

6.5.1 Qilu Pharma Corporation Information

6.5.2 Qilu Pharma Description and Business Overview

6.5.3 Qilu Pharma Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Sales, Revenue and Gross Margin (2017-2022)

6.5.4 Qilu Pharma Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Portfolio

6.5.5 Qilu Pharma Recent Developments/Updates

6.6 Teva

6.6.1 Teva Corporation Information

6.6.2 Teva Description and Business Overview

6.6.3 Teva Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Sales, Revenue and Gross Margin (2017-2022)

6.6.4 Teva Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Portfolio

6.6.5 Teva Recent Developments/Updates

6.7 Novartis

6.6.1 Novartis Corporation Information

6.6.2 Novartis Description and Business Overview

6.6.3 Novartis Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Sales, Revenue and Gross Margin (2017-2022)

6.4.4 Novartis Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Portfolio

6.7.5 Novartis Recent Developments/Updates

6.8 Roche

6.8.1 Roche Corporation Information

6.8.2 Roche Description and Business Overview

6.8.3 Roche Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Sales, Revenue and Gross Margin (2017-2022)

6.8.4 Roche Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Portfolio

6.8.5 Roche Recent Developments/Updates

6.9 Mylan

6.9.1 Mylan Corporation Information

6.9.2 Mylan Description and Business Overview

6.9.3 Mylan Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Sales, Revenue and Gross Margin (2017-2022)

6.9.4 Mylan Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Portfolio

6.9.5 Mylan Recent Developments/Updates

6.10 Baxter

6.10.1 Baxter Corporation Information

6.10.2 Baxter Description and Business Overview

6.10.3 Baxter Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Sales, Revenue and Gross Margin (2017-2022)

6.10.4 Baxter Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Portfolio

6.10.5 Baxter Recent Developments/Updates

6.11 GSK

6.11.1 GSK Corporation Information

6.11.2 GSK Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Description and Business Overview

6.11.3 GSK Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Sales, Revenue and Gross Margin (2017-2022)

6.11.4 GSK Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Portfolio

6.11.5 GSK Recent Developments/Updates

6.12 Helsinn

6.12.1 Helsinn Corporation Information

6.12.2 Helsinn Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Description and Business Overview

6.12.3 Helsinn Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Sales, Revenue and Gross Margin (2017-2022)

6.12.4 Helsinn Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Portfolio

6.12.5 Helsinn Recent Developments/Updates

6.13 Southwest Pharma

6.13.1 Southwest Pharma Corporation Information

6.13.2 Southwest Pharma Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Description and Business Overview

6.13.3 Southwest Pharma Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Sales, Revenue and Gross Margin (2017-2022)

6.13.4 Southwest Pharma Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Portfolio

6.13.5 Southwest Pharma Recent Developments/Updates

6.14 Haisco

6.14.1 Haisco Corporation Information

6.14.2 Haisco Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Description and Business Overview

6.14.3 Haisco Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Sales, Revenue and Gross Margin (2017-2022)

6.14.4 Haisco Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Portfolio

6.14.5 Haisco Recent Developments/Updates

6.15 Sun Pharma

6.15.1 Sun Pharma Corporation Information

6.15.2 Sun Pharma Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Description and Business Overview

6.15.3 Sun Pharma Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Sales, Revenue and Gross Margin (2017-2022)

6.15.4 Sun Pharma Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Product Portfolio

6.15.5 Sun Pharma Recent Developments/Updates

7 Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Manufacturing Cost Analysis

7.1 Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Key Raw Materials Analysis

7.1.1 Key Raw Materials

7.1.2 Key Suppliers of Raw Materials

7.2 Proportion of Manufacturing Cost Structure

7.3 Manufacturing Process Analysis of Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs

7.4 Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

8.1 Marketing Channel

8.2 Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Distributors List

8.3 Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Customers

9 Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Dynamics

9.1 Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Industry Trends

9.2 Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Drivers

9.3 Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Challenges

9.4 Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Restraints

10 Global Market Forecast

10.1 Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Estimates and Projections by Type

10.1.1 Global Forecasted Sales of Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs by Type (2023-2028)

10.1.2 Global Forecasted Revenue of Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs by Type (2023-2028)

10.2 Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Estimates and Projections by Application

10.2.1 Global Forecasted Sales of Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs by Application (2023-2028)

10.2.2 Global Forecasted Revenue of Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs by Application (2023-2028)

10.3 Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs Market Estimates and Projections by Region

10.3.1 Global Forecasted Sales of Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs by Region (2023-2028)

10.3.2 Global Forecasted Revenue of Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs by Region (2023-2028)

11 Research Finding and Conclusion

12 Methodology and Data Source

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Author List

12.4 Disclaimer

Choose License Type

Checkout Inquiry Sample